BACKGROUND: The aim of this study was to determine the optimal treatment for a patient with newly diagnosed prostate cancer weighing the individual's risk of disease progression against his risk of non-cancer death. METHODS: We developed a predictive model incorporating clinicopathological tumor variables, patient age, comorbidity status, and primary treatment modality. We identified 6091 patients with clinically-localized prostate cancer managed with radical prostatectomy (n=4117) or radiation therapy (n=1974) from the Cancer of the Prostate Strategic Urologic Research Endeavor database. Fine and Gray competing-risks proportional hazards regression models were used to calculate the risks of prostate cancer-specific mortality (PCSM) and non-prostate cancer death and to generate a nomogram. RESULTS: The median follow-up after treatment was 53 months (interquartile range 30, 80 months). In total, 983 men died during follow-up, including 167 who died of prostate cancer and 816 who died of non-prostate cancer causes. On multivariate analysis, higher Cancer of the Prostate Risk Assessment score and primary treatment with radiation were associated with an increased risk of PCSM, whereas older age, African-American race, and treatment with radiation predicted non-prostate cancer death. The number of comorbidities and receipt of androgen deprivation therapy correlated with an increased risk of non-prostate cancer death, but not PCSM. The resulting nomogram allows quantification and comparison of the 10-year risk of PCSM and non-prostate cancer death. CONCLUSIONS: Integrating clinicopathological variables with comorbid conditions in a competing-risks model affords quantification and comparison of relative probabilities of PCSM and non-prostate cancer death following treatment. Our model thereby facilitates an individualized approach for counseling patients regarding prostate cancer management.
BACKGROUND: The aim of this study was to determine the optimal treatment for a patient with newly diagnosed prostate cancer weighing the individual's risk of disease progression against his risk of non-cancer death. METHODS: We developed a predictive model incorporating clinicopathological tumor variables, patient age, comorbidity status, and primary treatment modality. We identified 6091 patients with clinically-localized prostate cancer managed with radical prostatectomy (n=4117) or radiation therapy (n=1974) from the Cancer of the Prostate Strategic Urologic Research Endeavor database. Fine and Gray competing-risks proportional hazards regression models were used to calculate the risks of prostate cancer-specific mortality (PCSM) and non-prostate cancer death and to generate a nomogram. RESULTS: The median follow-up after treatment was 53 months (interquartile range 30, 80 months). In total, 983 men died during follow-up, including 167 who died of prostate cancer and 816 who died of non-prostate cancer causes. On multivariate analysis, higher Cancer of the Prostate Risk Assessment score and primary treatment with radiation were associated with an increased risk of PCSM, whereas older age, African-American race, and treatment with radiation predicted non-prostate cancer death. The number of comorbidities and receipt of androgen deprivation therapy correlated with an increased risk of non-prostate cancer death, but not PCSM. The resulting nomogram allows quantification and comparison of the 10-year risk of PCSM and non-prostate cancer death. CONCLUSIONS: Integrating clinicopathological variables with comorbid conditions in a competing-risks model affords quantification and comparison of relative probabilities of PCSM and non-prostate cancer death following treatment. Our model thereby facilitates an individualized approach for counseling patients regarding prostate cancer management.
Authors: Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen Journal: J Urol Date: 2007-06 Impact factor: 7.450
Authors: L C Harlan; A Potosky; F D Gilliland; R Hoffman; P C Albertsen; A S Hamilton; J W Eley; J L Stanford; R A Stephenson Journal: J Natl Cancer Inst Date: 2001-12-19 Impact factor: 13.506
Authors: P A Rochon; J N Katz; L A Morrow; R McGlinchey-Berroth; M M Ahlquist; M Sarkarati; K L Minaker Journal: Med Care Date: 1996-11 Impact factor: 2.983
Authors: S Houterman; M L G Janssen-Heijnen; C D G W Verheij; P J M Kil; H A van den Berg; J W Coebergh Journal: Prostate Cancer Prostatic Dis Date: 2006-03-14 Impact factor: 5.554
Authors: Paige L Marr; Eric P Elkin; Shelley A Arredondo; Jeanette M Broering; Janeen DuChane; Peter R Carroll Journal: J Urol Date: 2006-04 Impact factor: 7.450
Authors: Jochen Walz; Andrea Gallina; Fred Saad; Francesco Montorsi; Paul Perrotte; Shahrokh F Shariat; Claudio Jeldres; Markus Graefen; Francois Bénard; Michael McCormack; Luc Valiquette; Pierre I Karakiewicz Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: J B Eifler; J Alvarez; T Koyama; R M Conwill; C R Ritch; K E Hoffman; M J Resnick; D F Penson; D A Barocas Journal: J Urol Date: 2016-10-27 Impact factor: 7.450
Authors: Anthony T Corcoran; Marc C Smaldone; Brian L Egleston; Jay Simhan; Serge Ginzburg; Todd M Morgan; John Walton; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Robert G Uzzo; Alexander Kutikov Journal: BJU Int Date: 2013-07 Impact factor: 5.588
Authors: Kenneth G Nepple; Andrew J Stephenson; Dorina Kallogjeri; Jeff Michalski; Robert L Grubb; Seth A Strope; Jennifer Haslag-Minoff; Jay F Piccirillo; Jay P Ciezki; Eric A Klein; Chandana A Reddy; Changhong Yu; Michael W Kattan; Adam S Kibel Journal: Eur Urol Date: 2013-03-13 Impact factor: 20.096
Authors: Alexander Kutikov; Brian L Egleston; Daniel Canter; Marc C Smaldone; Yu-Ning Wong; Robert G Uzzo Journal: J Urol Date: 2012-10-18 Impact factor: 7.450
Authors: Linda G W Kerkmeijer; Evelyn M Monninkhof; Inge M van Oort; Henk G van der Poel; Gert de Meerleer; Marco van Vulpen Journal: World J Urol Date: 2015-09-29 Impact factor: 4.226
Authors: D Sundi; V M Wang; P M Pierorazio; M Han; T J Bivalacqua; M W Ball; E S Antonarakis; A W Partin; E M Schaeffer; A E Ross Journal: Prostate Cancer Prostatic Dis Date: 2013-11-05 Impact factor: 5.554